<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695032</url>
  </required_header>
  <id_info>
    <org_study_id>07GENE03</org_study_id>
    <secondary_id>ICREGAUD-TOXIPLAT</secondary_id>
    <secondary_id>ICREGAUD-07-GENE-03</secondary_id>
    <secondary_id>EUDRACT-2007-004251-12</secondary_id>
    <secondary_id>INCA-RECF0479</secondary_id>
    <nct_id>NCT00695032</nct_id>
  </id_info>
  <brief_title>Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors</brief_title>
  <official_title>Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory
      may help doctors learn more about changes that occur in DNA and identify biomarkers related
      to cancer. It may also help doctors predict how patients will respond to treatment.

      PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and
      ifosfamide for solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Identify and evaluate the early biomarkers of renal toxicity in patients with solid
           tumors treated with cisplatin and ifosfamide.

      Secondary

        -  Correlate the modification of biomarker studies and blood concentrations of cisplatin.

      OUTLINE: Patients receive standard chemotherapy comprising cisplatin and/or ifosfamide.

      Blood and urine samples are collected on days 1 and 2 (or day 3 if receiving ifosfamide only)
      during the first 3 courses. Samples are analyzed to determine plasma concentrations of
      residual cisplatin and to obtain urinary-protein profiles to measure renal toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of different biomarkers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity, specificity, and predictive value (positive and negative) of different markers</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Renal Toxicity</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a solid tumor

               -  Any location allowed

               -  Metastatic disease allowed

          -  Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Life expectancy &gt; 3 months

          -  Creatinine clearance â‰¥ 60 mL/min

          -  Must be available for follow up

          -  Not pregnant or nursing

          -  Not under guardianship or in prison

        Exclusion criteria:

          -  Prior drug-related nephrotoxicity

          -  Acute, uncontrolled urinary infection or &gt; 48-hours

          -  Pre-existing hemorrhagic cystitis

          -  Weak bladder

          -  Bilateral obstruction of urinary tract

          -  Insufficient, severe bone marrow hypoplasia

          -  Cardiorespiratory condition contraindicating hyperhydration

          -  Hearing impairment

          -  Hypersensitivity to cisplatin or products containing platinum

          -  Major psychiatric condition (severe depression, psychosis, dementia)

        PRIOR CONCURRENT THERAPY:

          -  No prior yellow fever vaccine, live attenuated vaccine, or phenytoin

          -  No concurrent participation in another biomedical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Chevreau-Dalbianco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2008</study_first_submitted>
  <study_first_submitted_qc>June 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal toxicity</keyword>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

